Item nanme:Moxifloxacin Hydrochloride Tablets Item character:This product is dark red film coated tablets
Indication: Moxifloxacin is indicated for adults (≥ 18 years old) with upper and lower respiratory tract infections, such as acute sinusitis, acute exacerbations of chronic bronchitis, community-acquired pneumonia, and skin and soft tissue infections
Item specifications: 0.4g*3tab/box
Usage and dosage:Dose range
Oral administration of moxifloxacin tablets is recommended for any indication . 4 g (1 tablet), once a day.
4 g (1 tablet), once a day.
Oral administration of moxifloxacin tablets is recommended for any indication
Oral administration of moxifloxacin tablets is recommended for any indication
Oral administration of moxifloxacin tablets is recommended for any indication .
Oral administration of moxifloxacin tablets is recommended for any indication
Oral administration of moxifloxacin tablets is recommended for any indication
Oral administration of moxifloxacin tablets is recommended for any indication
Oral administration of moxifloxacin tablets is recommended for any indication . 4 g (1 tablet), once a day.
4 g (1 tablet), once a day.
Oral administration of moxifloxacin tablets is recommended for any indication
Oral administration of moxifloxacin tablets is recommended for any indication
Oral administration of moxifloxacin tablets is recommended for any indication
Oral administration of moxifloxacin tablets is recommended for any indication
Oral administration of moxifloxacin tablets is recommended for any indication . 4 g (1 tablet), once a day.
4 g (1 tablet), once a day.
Oral administration of moxifloxacin tablets is recommended for any indication . 4 g (1 tablet), once a day. How to take it for adults The tablets were taken with water, and the time of taking was not affected by diet. Treatment time The treatment time should be determined according to the severity of symptoms or clinical reaction.
The treatment time should be determined according to the severity of symptoms or clinical reaction.
Oral administration of moxifloxacin tablets is recommended for any indication
Adverse reactions ADRs were classified according to the frequency of ciomsiii (n = 17951, including sequential therapy, n = 4583)
In the subgroup of patients receiving oral or intravenous sequential therapy, the following adverse reactions occurred more frequently:
Common: increased gamma glutamyl transpeptidase
Rare: ventricular tachycardia, hypotension, edema, antibiotic induced colitis (rare cases with fatal complications), various clinical manifestations of seizures (including seizures), hallucinations, kidney damage and renal failure (caused by dehydration, especially in elderly patients with nephropathy).
Taboo: Known to be allergic to any component of moxifloxacin, or other quinolones, or any excipients.
Pregnant and lactating women.
Due to the lack of clinical data on the use of moxifloxacin in patients with severe liver injury (child Pugh grade C) and patients with elevated transaminase more than 5 times the upper limit of normal value, moxifloxacin is prohibited in such patients.
Patients under 18 years old.
Matters needing attention: If some patients have hypersensitivity and allergy after taking it for the first time, they should inform the doctor immediately.
Very few patients, in the first time after taking, will occur by allergic reaction caused by life-threatening shock. In these cases
The patients should stop using baifule and give corresponding treatment (such as treatment for shock).
Moxifloxacin can prolong QT interval of ECG in some patients. Because women tend to have longer QTc intervals than men, they may be more sensitive to drugs that cause QTc prolongation. Older patients are also more susceptible to drugs related to QT interval. Because the extent of QT interval prolongation may increase with the increase of drug concentration. Therefore, it should not exceed the recommended dose and infusion rate (0.4g within 90 minutes). However, no association was observed between plasma concentration of baifule and prolonged QTc interval in patients with pneumonia. Prolonged QT interval can increase the risk of ventricular arrhythmias including torsade de pointe. In the clinical study of over 9000 patients treated by the treatment of the treatment of QTc, there was no cardiovascular morbidity or mortality due to prolonged interval. However, some potential conditions could increase the incidence rate of ventricular arrhythmia.
[u] Due to the lack of clinical experience of bifidole in the following patient populations, the use of the drug should be avoided in these populations
·Patients with known QT interval prolongation;
·Patients with uncorrectable hypokalemia;
·Patients receiving class I (e.g. quinidine, procainamide) or class III (e.g. amiodarone, sotalol) antiarrhythmic drugs.
[u] Moxifloxacin should be used cautiously in the following cases because the cumulative effect of bifidole on QT interval can not be ruled out:
·The patients received concomitant treatment with QT prolonging drugs, such as cisapride, erythromycin, antipsychotics and tricyclic antidepressants;
·At present, patients have arrhythmogenic conditions, such as bradycardia and acute myocardial ischemia;
·Patients with liver cirrhosis, in these patients can not rule out the previous QT interval extension;
·Female and elderly patients may be more sensitive to the drugs that cause QTc prolongation.
Fule has been reported to cause fulminant hepatitis, which may lead to liver failure (including death cases) (see [adverse reactions]). If liver failure related symptoms occur, patients should be advised to contact a doctor immediately before continuing treatment.
The use of quinolones can induce seizures. For patients with known or suspected central nervous system diseases that can cause seizures or reduce the seizure threshold, we should pay attention to the use of baifule.
Antibiotic associated enteritis has been reported during the use of broad-spectrum antibiotics including bifidole. Therefore, it is important to consider this diagnosis when patients develop severe diarrhea during the use of bifidole. In this case, we need to take adequate treatment measures immediately. In patients with severe diarrhea, we should not use drugs that can inhibit gastrointestinal peristalsis.
Patients with myasthenia gravis should be careful to use baifule, because it can aggravate the symptoms.
Tendinitis and tendon rupture may occur in the use of quinolones including moxifloxacin, especially in elderly patients and patients treated with corticosteroids at the same time; there have been reports of cases several months after the completion of treatment. Once the symptoms of pain or inflammation appear, the patient needs to stop taking medicine and rest the affected limb.
It has been proved that quinolones can cause photosensitive reaction in patients. However, in the specially designed preclinical and clinical studies, no photosensitive response of baifule was observed. In addition, there is no clinical evidence to prove that baifule can cause photosensitive reaction. Nevertheless, patients should be advised to avoid overexposure to UV and sunlight.
For patients with complex pelvic infection (such as tubal ovarian or pelvic abscess), intravenous administration should be considered, but oral administration of 0.4g baifule tablets is not recommended.
Moxifloxacin is not recommended for the treatment of MRSA infection. If MRSA infection is suspected or confirmed, appropriate antibiotics should be used to start treatment.
The in vitro activity of moxifloxacin may interfere with the culture test of Mycobacterium by inhibiting the growth of Mycobacterium. Therefore, the sample results may be false negative for patients who are using baifule.
It has been reported that in patients receiving varonone drugs, including baifule, there have been polyneuropathy leading to paresthesia, hypoesthesia, insensitive or feeble sensation or sensorimotor. If the patient has neurological symptoms such as pain, burning, tingling, numbness or weakness during the treatment with bifidole, it is recommended to inform the doctor before continuing the treatment with bifidole (see [adverse reactions]).
Psychiatric reactions, including moxifloxacin, may occur even after the first use of flufenolones. In rare cases, depressive or psychotic reactions developed into suicidal ideation and self injurious behavior, such as attempted suicide (see [adverse reactions]). If the patient has the above reaction, should stop using baifule and carry on the appropriate disease treatment. It is recommended to be careful when using baifule in patients with mental illness or with a history of mental illness.
Because the prevalence of fluoroquinolone resistant Neisseria gonorrhoeae is increasing, moxifloxacin monotherapy should be avoided in patients with pelvic infectious diseases, unless it can be excluded as fluoroquinolone resistant Neisseria gonorrhoeae. If the infection of Neisseria gonorrhoeae resistant to flufenolone cannot be excluded, an additional antibiotic (e.g. cephalosporin) should be considered in Moxifloxacin treatment.
Flufenolones, including moxifloxacin, may impair the ability of the patient to drive or operate machinery due to central nervous system (CNS) reactions and vision abnormalities (see [adverse reactions]).
Medication for pregnant and lactating women: Pregnant women: the safety of moxifloxacin in human pregnancy has not been confirmed. Quinolones can cause reversible joint injury in children. However, this effect has not been reported in the fetus of pregnant drug users. Animal studies have shown that moxifloxacin has reproductive toxicity, but its potential risk to human remains unclear. Therefore, moxifloxacin is forbidden in pregnant women.
Lactating women: like other quinolones, moxifloxacin can cause cartilage damage in weight-bearing joints of juvenile experimental animals. Preclinical studies have confirmed that a small amount of moxifloxacin can be distributed in human milk, and there is a lack of data on lactating women. Therefore, moxifloxacin is forbidden to lactating women.
FAQ 1.who are we? We are based in Fujian, China, start from 2000,sell to North America(40.00%),Southeast Asia(25.00%),Western Europe(25.00%),Africa(10.00%).There are total about 50 people in our office.
2. how can we guarantee quality? Always a pre-production sample before mass production; Always final Inspection before shipment;
3.what can you buy from us? Pharmaceutical production lines,Intermediates,APIs,Finished Drug Preparations & Vaccines.
4. why should you buy from us not from other suppliers? We have our own manufacture factories and one professional sales team working for the clients all over the world.
5. what services can we provide? Accepted Delivery Terms: FOB,CIF,EXW,DDP,Express Delivery; Accepted Payment Currency:USD,EUR,CAD,AUD,GBP,CNY; Accepted Payment Type: T/T,L/C,PayPal,Western Union; Language Spoken:English,Chinese,Japanese
Our Ddvantage: 1. Quick delivery 2. Online payment 3. Quality assurance 4. Welcome big order 5. After-sales service 24 hours 6. Competitive advantage products 7. Our value information is "Quality is our culture" 8. Work with us to provide you with secure funds, your business is securely protected, our advantages
Our Service a) Free amples can be provided. b) Guide customers through professional technology and teach them how to use our products after sale c) Determine the lowest price of high-quality products 1. Skilled experience: Our company is a leading manufacturer of professional production in Chinapharmaceutical field for manyyears. 2. The highest quality: to ensure high quality, once any problems are found, the package will be re-shipped for you. 3. Safe transportation: by air express (FedEx, UPS, DHL, EMS). It is recommended that you choose the most professional freightforwarder. 4. Fast delivery: We have stock, so once payment is received, we can deliver quickly. 5. Quality service: We will provide you with enthusiastic after-sales service. If you have any questions, we will reply to youwithin 24 hours. 6. Competitive price: discounts will be obtained when making large orders.
Our Manufacture Factory Fuzhou FUL Fluid Equipment & Pharmaceutical Co., Ltd is a comprehensive enterprise which integrates R & D, production and construction of pharmaceutical production equipments, development and transfer of biotechnology, and cooperative production and sales of drugs and vaccines. The self-developed pharmaceutical production equipment branded FUL has been put into operation in many well-known pharmaceutical enterprises such as SINOPHARM, CSPC and also cooperates with many well-known pharmaceutical enterprises in production and sales, including pharmaceutical intermediates, APIs and finished drug preparations.
Fuzhou FUL Fluid Equipment & Pharmaceutical Co., Ltd business radiates to all levels, including direct supply cooperation with government departments and industry representatives, as well as establishing supply cooperation relationship with retail industry. We supply high quality, safe and effective medicines and medical equipment to governments, hospitals, clinics and licensed pharmacies in different countries with timely and effective services at reasonable prices.
At present Fuzhou FUL Fluid Equipment & Pharmaceutical Co., Ltd has the SINOPHARM authorization to sell its intermediates and APIs,and has the authorizations of CSPC & HUABEI PHARM sell its finished drug preparations;then FUL is the only manufacture in China which can supply the complete service from pharmaceutical produciton lines,intermediates and APIs to finished drug preparations and vaccines.Then we are seeking the professional pharmaceutical enterprices to work together for further cooperations.
){kind=link}